OmniAb, Inc.
Sylvain Lebreton has a diverse work experience spanning over several companies and roles. Sylvain currently holds the position of Associate Research Fellow at OmniAb, Inc. since November 2022. Prior to this, they worked at Icagen as an Associate Research Fellow from September 2022, and then as a Senior Principal Scientist from April 2020 to September 2022. Sylvain also served as a Senior Research Investigator at Icagen from July 2016 to April 2020. Before joining Icagen, Sylvain worked at Sanofi as a Senior Research Investigator from January 2012 to July 2016. Sylvain began their career at Sanofi-Aventis U.S. LLC as a Research Investigator from October 2007 to December 2011. Prior to that, they worked at Sanofi-Aventis France S.A. as a Research Investigator from September 2006 to September 2007. Sylvain also gained experience as a Research Associate at Rhone-Poulenc Rorer from March 1999 to September 1999, and as a Visiting Scientist at Selectide Corporation from October 1997 to February 1999. Sylvain started their career as a Laboratory Assistant at American Cyanamid from September 1995 to September 1996.
Sylvain Lebreton completed their education in a chronological order. Sylvain started by obtaining a Bachelor's degree from Kingston University, where the field of study is unknown. Sylvain then pursued a Ph.D. in Organic Chemistry from the University of Southampton, which they completed between 1999 and 2002. Following that, they enrolled in a postdoctoral program in Total Synthesis at UT Southwestern Medical Center from 2003 to 2006.
In addition to their formal education, Sylvain Lebreton has also obtained certifications in specific subjects. In 2016, they completed a course called "ADMET Process (Drug Metabolism, Pharmacokinetics, Toxicology, Predicting&Selecting Drug Compounds)" from UC San Diego Extension. In 2018, they also earned a certification in "Introduction to the Biology of Cancer" from Coursera.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.